Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-02-25

FDA Approved: TRIAMTERENE AND HYDROCHLOROTHIAZIDE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

The FDA approved a supplemental application for Triamterene and Hydrochlorothiazide from BluePoint Laboratories, enabling the marketing of this generic combinat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Triamterene and Hydrochlorothiazide (Triamterene and hydrochlorothiazide)

Snippet

SUPPL AP for TRIAMTERENE AND HYDROCHLOROTHIAZIDE (TRIAMTERENE AND HYDROCHLOROTHIAZIDE)